Corcept Therapeutics (CORT) Tops Q3 EPS by 3c, provides guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts CORT Hot Sheet
Price: $79.22 -3.31%
Financial Fact:
Research and development: 7.05M
Today's EPS Names:
COHR, ATS, SICP, More
Financial Fact:
Research and development: 7.05M
Today's EPS Names:
COHR, ATS, SICP, More
Join SI Premium – FREE
Corcept Therapeutics (NASDAQ: CORT) reported Q3 EPS of $0.16, $0.03 better than the analyst estimate of $0.13. Revenue for the quarter came in at $207.6 million versus the consensus estimate of $218.53 million.
GUIDANCE:
Corcept Therapeutics sees FY2025 revenue of $800-850 million, versus the consensus of $852.7 million.
For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Vertex (VERX) Tops Q3 EPS by 4c; Offers Guidance
- Stabilis Solutions, Inc. (SLNG) Tops Q3 EPS by 3c
- Eversource Energy (ES) Tops Q3 EPS by 18c; offers guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
